Amarin (AMRN) reported a loss of $0.09 per share in its second quarter, beating consensus forecast by 4 cents. The company reported revenue of $33.11 million, up 87% on a year-over-year basis. Revenue beat consensus forecast by $3.14 million.

Lexicon Pharmaceuticals (LXRX) reported a loss of $0.37 per share in its second quarter, beating consensus forecast by 3 cents. The company reported revenue of $20.09 million, beating consensus forecast by $7.73 million.

Paratek Pharmaceuticals (PRTK) reported a loss of $1.69 per share in its second quarter. The company ended the quarter with cash and cash equivalents of $150.4 million.

Intra-Cellular Therapies (ITCI) reported a loss of $0.71 per share in its second quarter, beating consensus forecast by 8 cents. The company�s revenue for the quarter was $0.23 million, up 283.3% on a year-over-year basis. Revenue beat consensus forecast by $0.21 million.

Dipexium (DPRX) reported a loss of $0.52 per share in its second quarter, beating consensus forecast by 2 cents. The company ended the quarter with cash and cash equivalents of $7.6 million.

Akorn (AKRX) reported second-quarter earnings of $0.58 per share, beating consensus forecast by 3 cents. The company�s revenue for the quarter was $280.73 million, up 27.1% on a year-over-year basis. Revenue beat consensus forecast by $7.74 million.